Artivion, Inc. (NYSE:AORT) SVP Marshall S. Stanton Sells 10,548 Shares

Artivion, Inc. (NYSE:AORT) SVP Marshall S. Stanton sold 10,548 shares of the firm’s stock in a transaction that occurred on Friday, May 9th. The shares were sold at an average price of $29.13, for a total transaction of $307,263.24. Following the completion of the sale, the senior vice president now directly owns 105,332 shares of the company’s stock, valued at approximately $3,068,321.16. This represents a 9.10% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Artivion Trading Down 0.8%

Shares of NYSE AORT traded down $0.23 during midday trading on Monday, reaching $28.69. 149,580 shares of the stock were exchanged, compared to its average volume of 317,010. The business has a 50-day simple moving average of $24.16 and a two-hundred day simple moving average of $27.22. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of -1,433.20 and a beta of 1.54. Artivion, Inc. has a 12 month low of $21.97 and a 12 month high of $32.33. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Monday, May 5th. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.06). The firm had revenue of $98.98 million for the quarter, compared to the consensus estimate of $94.81 million. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. As a group, equities research analysts expect that Artivion, Inc. will post 0.37 EPS for the current year.

Hedge Funds Weigh In On Artivion

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Barclays PLC lifted its position in Artivion by 346.3% in the 3rd quarter. Barclays PLC now owns 70,877 shares of the company’s stock valued at $1,888,000 after acquiring an additional 54,996 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Artivion by 394.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 97,903 shares of the company’s stock valued at $2,606,000 after acquiring an additional 78,120 shares in the last quarter. Calamos Advisors LLC lifted its position in Artivion by 113.7% in the 4th quarter. Calamos Advisors LLC now owns 63,029 shares of the company’s stock valued at $1,802,000 after acquiring an additional 33,541 shares in the last quarter. GAMMA Investing LLC lifted its position in Artivion by 21.8% in the 4th quarter. GAMMA Investing LLC now owns 2,772 shares of the company’s stock valued at $79,000 after acquiring an additional 497 shares in the last quarter. Finally, Franklin Resources Inc. increased its stake in Artivion by 14.4% in the 3rd quarter. Franklin Resources Inc. now owns 21,107 shares of the company’s stock valued at $553,000 after buying an additional 2,663 shares during the last quarter. 86.37% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Artivion in a research note on Tuesday, May 6th. JMP Securities reaffirmed a “market outperform” rating and issued a $33.00 price objective on shares of Artivion in a research note on Tuesday, May 6th. Stifel Nicolaus reduced their price objective on shares of Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday, February 25th. Finally, Citizens Jmp raised shares of Artivion to a “strong-buy” rating in a research note on Tuesday, May 6th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $31.40.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.